WASHINGTON, March 3, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Financial Officer John Johnson and Vice President, Investor Relations, Seth Frank will participate in upcoming investor conferences, including meetings with institutional investors and presentations.
A live audio-only webcast and replay for these events will be available on the investor relations section of Evolent's website at ir.evolenthealth.com/, unless otherwise noted below.
About Evolent Health
Evolent Health delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.
Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent Health, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)
Last Trade: | US$27.74 |
Daily Change: | -0.07 -0.25 |
Daily Volume: | 655,581 |
Market Cap: | US$3.160B |
February 22, 2024 February 14, 2024 December 05, 2023 November 02, 2023 August 24, 2023 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB